A Phase 1/2 clinical trial is evaluating the safety and effectiveness of a cutting-edge immunotherapy called extracorporeal photopheresis in people with multiple sclerosis (MS). The study, dubbed PHOMS (NCT05168384), is enrolling up to 45 adults with relapsing-remitting MS (RRMS) and secondary progressive MS (SPMS) at a…
News
A single infusion of FibroBiologics‘ investigational cell therapy, CYMS101, was able to inhibit disease activity in a mouse model of multiple sclerosis (MS), and appeared safe in early MS clinical trials, the company announced in a press release. Data from the mouse and human studies were…
The presence of self-reactive antibodies, typically seen in autoimmune diseases like scleroderma, may be common among patients with multiple sclerosis (MS). That finding from a small study indicates high levels of these antinuclear antibodies were correlated with relapse status and ongoing inflammation in MS. The study, “Antinuclear…
Lyvispah — a dissolvable granular formulation of baclofen — is now commercially available in the U.S. for adults and adolescents, 12 and older, with spasticity associated with multiple sclerosis (MS) and other spinal cord disorders. In people with MS, the strawberry-flavored formulation is particularly suitable to ease flexor…
Worsening disability was associated with worry about COVID-19 in people with multiple sclerosis (MS) living in the U.S. and Italy, a study evaluating the pandemic’s impact has found. In both countries, MS patients with greater psychological disabilities, such as depression, were more likely to have worrying thoughts, while those…
Acknowledging advances in early detection of multiple sclerosis (MS), the Paralyzed Veterans of America (PVA) is broadening its membership and inviting all veterans with the progressive neurodegenerative disorder to join the nonprofit organization. Now, all veterans with MS are eligible for PVA membership and the same support available to…
The U.S. Food and Drug Administration (FDA) is extending by three months its review of ublituximab, an experimental anti-CD20 antibody being developed by TG Therapeutics for relapsing forms of multiple sclerosis (MS). The FDA had agreed to review the company’s application requesting ublituximab’s approval late last year, and…
A new scoring system might more precisely evaluate disease development, severity, and treatment response in a commonly used mouse model of multiple sclerosis (MS) known as the experimental autoimmune encephalomyelitis or EAE model, scientists report. This scoring system, called “I AM D EAE,” was described in the study, “…
The U.S. Department of Defense (DOD) has awarded $3.9 million to fund clinical research to test the impact of a low-glycemic diet on physical, cognitive, and psychological function in people with multiple sclerosis (MS). The four-year project, called “Impact of diet quality and calorie restriction on physical function and…
Novartis’ Mayzent (siponimod) and Kesimpta (ofatumumab) are gaining ground among multiple sclerosis (MS) therapies in Canada, according to the latest Spherix Global Insights’ report. “Following an eventful 2021 that included the launch of two new brands — Novartis’ Kesimpta and BMS’ Zeposia — and generic versions of Biogen’s…
Among multiple sclerosis (MS) patients starting on Lemtrada (alemtuzumab), an early decrease in the leakiness of the blood-brain barrier (BBB) is associated with a lower likelihood of disease activity after two years, according to a new study. The blood-brain barrier is a cellular divisor that regulates which substances…
Repeated fecal transplants from healthy donors were safe and well-tolerated in a small group of people with relapsing-remitting multiple sclerosis (RRMS), a study reported. Treatment also showed a potential to ease intestinal permeability in MS and enrich the presence of protective microbes in the gut. Given that the trial…
Treatment with Ponvory (ponesimod) significantly reduces the risk of worsening disability or new relapses for people with relapsing forms of multiple sclerosis (MS) compared with a placebo, according to a new analysis funded by the therapy’s maker Janssen. The study, “Comparative Efficacy of Relapsing Multiple Sclerosis Therapies:…
People with multiple sclerosis (MS) are more likely to have lesions in three regions of the brain — the anterior temporal horn, periventricular region, and cerebellar hemisphere — compared with people with other inflammatory brain diseases, a study reports. Looking for lesions in these parts of the brain may…
A five-week, high-intensity video game-based exercise program called exergaming outperformed other forms of exercise at easing symptoms and improving life quality in people with multiple sclerosis (MS), a small trial found. While all exercise programs slowed symptom worsening over two subsequent years of lower-intensity exercises, exergaming led to the…
People with relapsing multiple sclerosis who have disability progression, but no clinical relapses, show significantly faster brain shrinkage, or atrophy, than those with a stable disease, a study shows. There were no significant differences in the brain atrophy rate between patients with progression independent of relapse activity (PIRA) and…
From sharing stories to heralding support networks, people across the globe are preparing to mark World MS Day, observed annually on May 30th to heighten awareness of multiple sclerosis (MS), a progressive neurodegenerative disorder and the 2.8 million people it’s thought to affect. Event activities take place throughout May…
Regular feedback from doctors about dosing data and health status is associated with high and sustained treatment adherence to Rebif (interferon beta-1a) among multiple sclerosis (MS) patients using the RebiSmart autoinjector, a two-year observational study shows. This study’s level of treatment adherence — 97.9% — was comparable or superior to the…
Persistent use of a single disease-modifying therapy (DMT) over a three-year period was low among people with relapsing forms of multiple sclerosis (MS), a U.S. study found. DMT discontinuations or switches were initiated in some cases by prescribers, specialty pharmacists, or patients for reasons that included treatment side…
People with high levels of free vitamin D in circulation before the age of 20 have a lower risk of developing multiple sclerosis (MS) later in life, a new study suggests. A significantly lower risk was also observed among people who, at ages 30–39, had elevated levels of a…
People with progressive forms of multiple sclerosis (MS) and those with greater MS-related disability have a significantly greater risk of serious infections relative to people without the disease, according to a population-based study in Sweden. Notably, these associations were observed regardless of the use of disease-modifying therapies, many…
Genetic variants that contribute to a high body mass index (BMI) during childhood are associated with an increased risk of developing multiple sclerosis (MS), a study found. The relationship is likely influenced by the fact that a higher BMI in childhood is linked to obesity in adulthood and a “longer…
ABX-002, an experimental treatment for multiple sclerosis (MS) being developed by Autobahn Therapeutics, promoted the restoration of the myelin sheath in preclinical models of the disease, new data show. The research, which specifically tested an analog of ABX-002 called LL-341070, will be presented by Autobahn’s academic collaborators at…
Aquatic exercise is used less often by people with multiple sclerosis (MS) than land-based exercise, but it’s generally well liked by those who use it, a patient survey found. A lack of pool access and associated expenses remain significant barriers to aquatic exercise. The team also found that exercise…
Among people with relapsing-remitting multiple sclerosis (RRMS), those who are married and have more formal education are more likely to take treatments as recommended, according to a new study from Iran. The study, “Effects of Disease-Modifying Treatments discontinuation in patients with Relapsing-Remitting Multiple Sclerosis: A 5…
Gilenya (fingolimod) and Tysabri (natalizumab) were more effective at lowering relapse rates in children with multiple sclerosis (MS) than interferon-beta, according to a recent meta-analysis. Findings like these can be leveraged for better clinical trial design, the researchers wrote. If used to determine “historical” relapse rates that…
The South Florida craft brew company 3 Mavins’ Beer is making it easy to support the Multiple Sclerosis Foundation’s programs and services on behalf of those who have the neurological disorder. Through a new partnership with the foundation, 3 Mavins’ is donating 3% of its profits from each can of…
Many people newly diagnosed with relapsing-remitting multiple sclerosis (RRMS) experience substantial “hidden disabilities,” such as depression or fatigue, a study highlights. Findings indicate that treatment with disease-modifying therapies generally does not affect the severity of these problems, at least in the short term. “Considering the substantial impact that hidden…
Taking Copaxone (glatiramer acetate), an approved therapy for relapsing forms of multiple sclerosis (MS), while breastfeeding does not appear to be harmful to infants during their first 18 months, according to a real-life study in Germany called COBRA. “In this study, we compared the development of 120 children in total, whose…
Among multiple sclerosis (MS) patients on rituximab, higher B-cell counts are predictive of a better antibody-based response to a vaccine for COVID-19, according to a new Swedish study. “In our study, the B-cell level in patients given Rituximab was the only factor that influenced the ability to form antibodies…